This activity has been designed to meet the educational needs of physician assistants and nurse practitioners in primary care with patients with type 1 or type 2 diabetes mellitus who are using or who may benefit from using insulin pump therapy.
Original Release Date: November 2011
Expiration Date: November 30, 2012
Estimated Time to Complete this Activity: 1 hour
Medium: Printed journal and online CE/CME
The primary objective of this educational initiative is to provide clinicians in primary care with the most up-to-date information regarding the use of insulin pump therapy for patients with type 1 or type 2 diabetes mellitus.
After completing this activity, the participant should be better able to:
Alexis M. Blount, RN, MSN, MPH, FNP-BC, CDE, is a nurse practitioner in the Pediatric
Endocrine Department at Walter Reed National
Military Medical Center in Bethesda, Maryland. Joe
Largay, PA-C, CDE, practices in the outpatient clinic
in the University of North Carolina Diabetes Care
Center and is Director of the Diabetes Care Center’s
Clinical Trials Program.
This program has been reviewed and is approved for
a maximum of 1.0 hour of American Academy of
Physician Assistants (AAPA) Category I CME credit
by the Physician Assistant Review Panel. Approval is
valid for one year from the issue date of November
2011. Participants may submit the self-assessment at
any time during that period.
This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
Successful completion of the self-assessment is required to earn Category I CME credit. Successful
completion is defined as a cumulative score of at least
Nurse Practitioners: This program has been approved by the Nurse Practitioner Association New York State (The NPA) for 1.0 contact hour.
DISCLOSURE OF CONFLICTS OF INTEREST
The faculty reported the following financial
relationships or relationships to products or devices they or their spouse/life partner have with
commercial interests related to the content of this
CME activity: Alexis M. Blount, RN, MSN, MPH, FNP-BC, CDE, is a certified pump trainer for
Medtronic Minimed, Omnipod, and Animas
pumps, for which she receives no remuneration; Joe Largay, PA-C, CDE, is a paid consultant for
Abbott Laboratories and Bristol-Myers Squibb
and has received grants and/or research support
from Amylin Pharmaceuticals, Andromeda Medical Systems, Hoffman-LaRoche, Immune Tolerance Network, Johnson & Johnson, Eli Lilly and
Company, Medtronic, Merck, Novo Nordisk,
Osiris Therapeutics, Pfizer, NIAID and NHLBI,
NIH, and Tolerx.
METHOD OF PARTICIPATION
The fee for
participating and receiving CME credit for this activity is $10.00. During the period November 2011 through November 30, 2012, participants must:
If you have any questions, e-mail CR.firstname.lastname@example.org. Upon successful completion of
an online posttest, with a score of 70% or better,
and the completion of the online activity evaluation form, a statement of credit will be made available immediately.
DISCLOSURE OF UNLABELED USE
educational activity may contain discussion of published and/or investigational uses of agents that are
not indicated by the FDA. AAPA, The NPA, and
Quadrant HealthCom Inc. do not recommend the
use of any agent outside of the labeled indications.
The opinions expressed in this educational activity
are those of the faculty and do not necessarily represent the views of AAPA, The NPA, or Quadrant
HealthCom Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications,
Participants have an implied responsibility to use the newly acquired information
to enhance patient outcomes and their own professional development. The information presented in
this activity is not meant to serve as a guideline for
patient management. Any procedures, medications,
or other courses of diagnosis or treatment discussed
or suggested in this activity should not be used by
clinicians without evaluation of their patient’s conditions and the possible contraindications or dangers in use, review of any applicable manufacturer’s
product information, and comparison with recommendations of other authorities.